Gene expression analysis on the liver of cholestyramine-treated type 2 diabetic model mice

Biomedicine and Pharmacotherapy

Volumn 64, Issue 6, 2010, Pages 373-378

  Matsumoto, Kenji ^a   Yokoyama, Shin Ichiro ^a  

^a Gifu Prefectural Research Institute for Bioengineering   (Japan)

Author keywords

Bile acid binding agent; Cholestyramine; DNA microarray; Type 2 diabetes

Indexed keywords

CHOLESTEROL; COLESTYRAMINE; GLUCOSE; INSULIN; LIVER X RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA MICROARRAY; FATTY LIVER; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPID DIET; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BILE ACIDS AND SALTS; CHOLESTEROL; CHOLESTYRAMINE RESIN; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION PROFILING; HYPERINSULINISM; LIVER; MALE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORPHAN NUCLEAR RECEPTORS; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; WEIGHT GAIN;

EID: 77954312931     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.02.008     Document Type: Article

References (21)

1. Houten S.M., Watanebe M., Auwerx J. Endocrine functions of bile acids. EMBO J 2006, 25:1419-1425.
2. Kramer W., Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr Med Chem 2006, 13:997-1016.
3. Kobayashi M., Ikegami H., Fujisawa T., Nojima K., Kawabata Y., Noso S., et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007, 56:239-247.
4. Yamakawa T., Takano T., Utsunomiya H., Kadonosono K., Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocrine J 2007, 54:53-58.
5. Fonseca V.A., Rosenstock J., Wang A.C., Truitt K.E., Jones M.R. Colesevelam HC1 improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008, 31:1479-1484.
6. Shibata M., Yasida B. New experimental congenital diabetic mice (N.S.Y mice). Tohoku J Exp Med 1980, 130:139-142.
7. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
8. Matsumoto K., Hiraiwa N., Yoshiki A., Ohnishi M., Kusakabe M. PDGF receptor-alpha deficiency in glomerular mesangial cells of tenascin-C knockout mice. Biochem Biophys Res Commun 2002, 290:1220-1227.
9. Stevens A, Lowe JS. Liver. In: Cool L editor. Human histology 2nd ed. Mosby; 1997. p. 215-26.
10. Kim J.H., Lee J.N., Paik Y.K. Cholesterol biosynthesis from lanosterol, A concerted role for Sp1 and NF-Y-binding sites for sterol-mediated regulation of rat 7-dehydrocholesterol reductase gene expression. J Biol Chem 2001, 276:18153-18160.
11. Amemiya-Kudo M., Shimano H., Hasty A.H., Yahagi N., Yoshikawa T., Matsuzaka T., et al. Transcriptonal activities of nuclear SREBP-la, -lc, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 2002, 43:1220-1235.
12. Yu L., Hammer R.E., Li-Hawkins J., Von Bergmann K., Lutjohann D., Cohen J.C., et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A 2002, 99:16237-16242.
13. Zelcer N., Tontonoz P. Live X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006, 116:607-613.
14. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., Hobbs H., Mangelsdorf D.J. Regulation of ATP-binding cassette sterol transporters AGCG5 and ABCG8 by liver X receptor α and β. J Biol Chem 2002, 277:18793-18800.
15. Stulnig T.M., Steffensen K.R., Gao H., Reimers M., Dahlman-Wright K., Schuster G.U., et al. Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol Pharm 2002, 62:1299-1305.
16. Grefhorst A., Elzinga B.M., Voshol P.J., Plosch T., Kok T., Bloks V.W., et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002, 277:34182-34190.
17. Cao G., Beyer T.P., Yang X.P., Schmid R.J., Zhang Y., Bensch W.R., et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002, 277:39561-39565.
18. Sever N., Song B.L., Yabe D., Goldstein J.L., Brown M.S., DeBose-Boyd R.A. Insigdependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J Biol Chem 2003, 278:52479-52490.
19. Espenshade P.J. SREBPs: sterol-regulated transcription factors. J Cell Sci 2006, 119:973-976.
20. Engelking L.J., Kuriyama H., Hammer R.E., Horton J.D., Brown M.S., Goldstein J.L., et al. Overexpression of insig-1 in the livers of transgenic mice inhibits SREBP processing and reduce insulin-stimulated lipopogenesis. J Clin Invest 2004, 113:1168-1175.
21. Watanabe M., Houten S.M., Mataki C., Christoffolete M.A., Kim B.W., Sato H., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.